These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33105798)

  • 1. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH; Siim BG; Evans JW; Brown JM
    Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of tirapazamine by multiple reductases in the nucleus.
    Delahoussaye YM; Evans JW; Brown JM
    Biochem Pharmacol; 2001 Nov; 62(9):1201-9. PubMed ID: 11705453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
    Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
    Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
    Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
    J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
    Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
    Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
    Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
    Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO; Siim BG; Pruijn FB; Wilson WR
    Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage.
    Broekgaarden M; Weijer R; van Wijk AC; Cox RC; Egmond MR; Hoebe R; van Gulik TM; Heger M
    J Biomed Nanotechnol; 2017 Feb; 13(2):204-20. PubMed ID: 29377650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
    Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
    J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tirapazamine-embedded polyplatinum(iv) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy.
    Guo D; Xu S; Yasen W; Zhang C; Shen J; Huang Y; Chen D; Zhu X
    Biomater Sci; 2020 Jan; 8(2):694-701. PubMed ID: 31777870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
    Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
    J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
    Hellauer K; Lesage G; Sdicu AM; Turcotte B
    Mol Pharmacol; 2005 Nov; 68(5):1365-75. PubMed ID: 16061773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
    Cowen RL; Williams KJ; Chinje EC; Jaffar M; Sheppard FC; Telfer BA; Wind NS; Stratford IJ
    Cancer Res; 2004 Feb; 64(4):1396-402. PubMed ID: 14973055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).
    Chowdhury G; Junnotula V; Daniels JS; Greenberg MM; Gates KS
    J Am Chem Soc; 2007 Oct; 129(42):12870-7. PubMed ID: 17900117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.